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We provide a validated and rapid protocol for the solubil-
ization of amyloid b-peptide (Ab). This procedure
involves sequential solubilization using structure-breaking
organic solvents hexafluoroisopropanol and DMSO fol-
lowed by column purification. The low solubility and
tendency of Ab to aggregate considerably impede the
in vitro handling and biophysical or biological investi-
gation of Ab, despite the interest in this peptide because
of its implication in Alzheimer’s disease. The main
advantage of the proposed protocol over others is that it
results in standardized aggregate-free Ab peptide
samples that are biocompatible for cell culture studies
and yield reproducible aggregation kinetics and cytotoxi-
cities. This three-step protocol also enables the co-solubil-
ization of the longer Ab42 variant with Ab40 in ratios
relevant to Alzheimer’s disease.
Keywords: aggregation/amyloid beta peptide/
biocompatibility/in vitro studies/solubilization
Introduction
The importance of protein aggregation has become increas-
ingly clear in the last decades with the discovery of a link
between this phenomenon and a number of human diseases,
including scrapie (Prusiner et al., 1983), familial amyloidosis
(Costa et al., 1978) and Parkinson’s disease (Spillantini et al.,
1997). Among the proteins identified in amyloid plaques,
amyloid b (Ab) peptides are special because they constitute
what could be considered as the prototype of an intrinsically
unstructured sequence with an unusually high amphipathic
character. Also, they are directly implicated in Alzheimer’s
disease, one of the emerging threats of modern society. Ab
peptides are generated from amyloid precursor protein as a
result of sequential b-secretase and g-secretase proteolytic
activity (De Strooper et al., 1998; Vassar et al., 1999; Wolfe
et al., 1999). Imprecise cleavage specificity by g-secretase
results in the generation of a range of Ab peptides varying in
C-terminal length from 37 up to 46 amino acids (Wiltfang
et al., 2002; Lewczuk et al., 2003; Maddalena et al., 2004)
although the majority of this pool is composed of Ab40 and
Ab42 (Suzuki et al., 1994; Scheuner et al., 1996). It is now
thought that the Ab variation pattern in the brains of patients
with Alzheimer’s disease is reflected by a general elongation
of the Ab peptides through a modulated g-secretase activity
(Wiltfang et al., 2002; Lewczuk et al., 2003; Bentahir et al.,
2006). Familial mutations in the gene encoding for the inde-
pendent composites of the g-secretase complex all induce the
formation of longer Ab peptides, which appear to be directly
involved in plaque formation in the brains of Alzheimer’s
disease patients (Jarrett et al., 1993; Suzuki et al., 1994;
Scheuner et al., 1996). The extra residues in the elongated Ab
peptides are hydrophobic thus drastically influencing the solu-
bility and amyloidogenicity of the peptide. To effectively
study the impact of Ab on toxicity and to elucidate the struc-
tural pathway of aggregation and formation of toxic oligomers,
it is crucial to initiate the studies with a well-defined aggregate-
free Ab species. It is, however, difficult to deal with Ab pep-
tides precisely for the very reason that makes them interesting:
they are poorly soluble and aggregation-prone in aqueous sol-
utions. Proteins that are prone to aggregate under physiologi-
cally relevant conditions are usually characterized by high
hydrophobicity and/or low net charge (Chiti et al., 2003;
DuBay et al., 2004; Fernandez-Escamilla et al., 2004; Linding
et al., 2004). Apart from their tendency to induce pathological
conditions and high aggregation propensity, the low solubility
of these peptides also results in inherent difficulties in the
experimental handling and investigation by biophysical tech-
niques and in cell culture. Nevertheless, high-resolution
characterization of these proteins may provide the information
required to tackle key questions aiming at therapeutic target-
ing. In response to these technical difficulties that significantly
hamper the research into neurodegenerative diseases, a variety
of protocols to aid the solubilization of Ab are available in the
literature. However, these procedures often involve the use of
extremely alkaline (Fezoui et al., 2000) or acidic solutions
(Ward et al., 2000) or rely on the presence of organic solvents
(Bitan and Teplow, 2004), thus introducing biologically incom-
patible compounds and/or conditions that are toxic to cell cul-
tures. Filtration of freshly prepared Ab samples is also
frequently used to remove pre-existing aggregates, but often
leads to significantly reduced recovery of soluble Ab material
(Bernstein et al., 2005). It is therefore essential to develop a
robust and reproducible preparation protocol that allows the
solubilization of these peptides under biocompatible buffer
conditions.
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Here, we describe a new and validated procedure to solu-
bilize the amyloid b-peptide that circumvents the above-
mentioned problems and allows us to obtain appreciable
quantities of virtually aggregate-free material. The method
relies on the use of a sequential solubilization procedure with
organic solvents, followed by the complete removal of these
chemicals to provide a non-toxic environment that is suitable
for biophysical characterization. We validated the procedure
by demonstrating complete solubilization of the peptide and
providing evidence that all chemicals involved are effectively
removed from the peptide solution without introducing oxi-
dation of the peptide. By using Thioflavin T fluorescence
(Tht) assays and cell culture studies, we show that the result-
ing solutions exert highly reproducible aggregation kinetics
and toxicities. We conclude that our procedure provides
monomeric Ab preparations in a cell-biology-compatible
environment, and is suitable for biophysical characterization.
Materials and methods
Reagents
Escherichia coli expressed human recombinant Alzheimer’s
beta peptide 1–40, Ultra Pure HFIP (cat. A1153), 1–42
Ultra Pure HFIP (cat. A-1163) and their uniformly
15N-isotope-labeled variants (cat. A-1101-2 and A-1102-2,
resp.) were purchased from rPeptide. ImperialTM Protein Stain
(cat. 24615) was obtained from Pierce. Dimethyl sulfoxide,
minimum 99.5% GC (cat. D4540), Trizma base (cat. T6066),
Trizma hydrochloride (cat. T5941), 1,1,1,3,3,3-hexafluoro-
2-propanol (HFIP), 99þ% (cat. 105228) and disodium ethyle-
nediaminetetraacetate (EDTA) (cat. E4884) were obtained
from Sigma. Quick StartTM Bradford Dye Reagent (cat. 500–
0205) was purchased from BioRad. Invitrogen provided
Novexw 10–20% Tricine gels (cat. EC66252), SeeBluew Plus
2 pre-stained standard (1) (cat. LC5925), Novexw
Tris-Glycine SDS sample buffer (2) (cat. LC2676) and
Novexw Tricine SDS running buffer (10) (cat. LC1675).
Preparation of Ab peptide solutions
Various ratios of Ab42:Ab40 were prepared starting from
material previously stored in a 2208C freezer. The vials con-
taining 0.5 mg Ab-HFIP films were allowed to defrost at
room temperature (258C) for 10 min. A quantity of 0.5 mg
Ab40 or Ab42 was dissolved in 500 ml hexafluoroisopropa-
nol (HFIP). The sample was mixed vigorously using a vortex
for 1 min and visually inspected for efficient solubilization.
To prepare Ab42:Ab40 ratios, a gas tight syringe was used
to add together specific volumes of Ab40 in HFIP and Ab42
in HFIP to obtain a defined ratio of Ab42:Ab40 followed by
mixing using a vortex for 1 min. The preparation of specific
ratios is further reported by Kuperstein et al. (2010). The
HFIP was evaporated using a gentle stream of oxygen-free
nitrogen gas and, alternatively, argon gas can be used. Based
on an HFIP volume of 500 ml in each vial prior to drying
with nitrogen gas, the peptide/HFIP films were redissolved in
500 ml dimethyl sulfoxide (DMSO). Samples were mixed
using a vortex for 1 min and visually inspected for efficient
solubilization. Immediately thereafter, the Ab peptide sol-
utions were separated from the DMSO by means of a desalt-
ing column (HiTrapTM Desalting column (cat. 17-1408-01),
GE Healthcare) that was pre-equilibrated with 25 ml 50 mM
Tris-HCl, 1 mM EDTA buffer, pH 7.4. Other buffer systems,
including phosphate-buffered saline can also be used. The
500 ml sample was applied to the column using a 1 ml
syringe followed by additional injection of 1 ml buffer, the
flow-through was discarded. Subsequently, the peptide was
eluted from the column by the additional injection of 1 ml
buffer. Typically, the first 500 ml flow-through contained
100–120 mM peptide and the second 500 ml contained
lower Ab concentrations (40–50 mM), which results in a
yield of original Ab peptide of 80% based on Bradford
determination of the peptide concentration. The
Ab-containing samples were collected in pre-cooled low-
adhesion resin-coated polypropylene centrifuge tubes
(Bioplastics, cat. B74030). After concentration measurement
using the Bradford assay for protein determination (Bradford,
1976), both fractions were combined to yield the required
concentration of Ab. Samples were kept on ice directly on
elution and further experiments were proceeded with within
20 min after elution from the desalting column.
Oligomerization and fibrillization of Ab
Oligomer-enriched fractions (1.5–2 h incubation) or amyloid
fibrils (.1 week incubation) of Ab were prepared by incu-
bation of 50–100 mM Ab at 258C under quiescent con-
ditions in 50 mM Tris-HCl, 1 mM EDTA, pH 7.4 using
low-adhesion resin-coated polypropylene centrifuge tubes.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE)
Non-reducing SDS-PAGE was performed by incubating
10 ml Ab-containing solution in 15 ml Novex Tris-Glycine
SDS sample buffer. Samples were then loaded onto a
10–20% Tricine gel (Invitrogen) and the gel was run at
170 V for 40 min followed by staining with Imperial Protein
Stain (Pierce).
Thioflavin T (Tht) fluorescence
Aggregate-free Ab42 solutions at a concentration of 50 mM
were prepared as described above by further dilution using
50 mM Tris-HCl, 1 mM EDTA containing buffer and a final
concentration of 12 mM Tht. In order to evaluate the effect
of DMSO on the aggregation kinetics, various concentrations
of DMSO (1–10%) were added to the elution buffer of Ab.
In order to validate the effectiveness of the proposed three-
step solubilization procedure, Ab42 was also directly dis-
solved into buffer without organic solvent treatment. The
fibrillization kinetics of Ab were monitored in situ using a
Fluostar OPTIMA fluorescence plate reader at an excitation
wavelength of 440 nm and an emission wavelength of
480 nm. Fluorescence readings were recorded every 10 min
for a period of 7 h. Measurements were performed in tripli-
cate, the recorded values were averaged and standard devi-
ations were calculated. Background measurements included
buffer or buffer containing DMSO and 12 mM Tht.
Transmission electron microscopy (TEM)
Aliquots (5 ml) of the Ab preparation were adsorbed to car-
boncoated FormVar film on 400-mesh copper grids (Plano
GmbH, Germany) for 1 min. The grids were blotted, washed
twice in droplets of Milli-Q water and stained with 1%
(wt/vol) uranyl acetate. Samples were studied with a JEOL
JEM-1400 microscope at 80 kV (JEOL Ltd, Japan).
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Fourier transform infraRed spectroscopy (FT-IR)
An aggregate-free Ab42 solution was prepared as described
in the ‘Preparation of Ab peptide solutions’. The Ab con-
centration was adjusted to 100 mM by dilution using 50 mM
Tris-HCl, 1 mM EDTA containing buffer. Spectra of Ab42
were recorded directly on elution from the column and after
24 h incubation at 258C under quiescent conditions. To
evaluate the contribution of organic solvent components to
the FT-IR spectrum, 1% DMSO or 1% HFIP were directly
dissolved into 50 mM Tris-HCl, 1 mM EDTA containing
buffer. Buffer was used to record a blank signal. The
InfraRed spectra were recorded using a Bruker Tensor 27
infrared spectrophotometer (Bruker Optik GmbH, Ettlingen,
Germany) equipped with a Bio-ATR II accessory. Spectra
were recorded at a spectral resolution of 4 cm21 and 120
accumulations were performed per measurement at a wave-
number range from 900 to 3500 cm21. Analysis of the
spectra involved blank (buffer) and baseline subtraction from
the obtained spectra and rescaling in a wavenumber range
from 900 to 1800 cm21.
Electrospray-ionization mass spectrometry (ESI-MS)
Ab42 was prepared as described in the ‘Preparation of Ab
peptide solutions’, but the column elution step was disre-
garded. The concentrated Ab42 solution in DMSO was
diluted 100 in acetonitrile:water (1:1) containing 1% acetic
acid to a final concentration of 2 mM Ab. Positive-ion mass
spectra were recorded on an orthogonal acceleration quadru-
pole time-of-flight mass spectrometer (Q-Tof-2, Micromass,
Manchester, UK) equipped with a standard electrospray
probe (Z-spray) and controlled by a datasystem running
MassLynx 3.4 (Micromass, Manchester, UK) and cone
voltage was set to 30 V, capillary voltage was 3 kV. Spectra
were recorded from m/z 600 to m/z 1600. Scan time was set
to 4.9 s with an interscan time of 0.1 s. At least 10 spectra
were acquired and averaged. Deconvolution was performed
using the MaxEnt algorithm included in the software.
Nuclear magnetic resonance spectroscopy (NMR)
Uniformly 15N-labeled Ab40 and Ab42 peptides were
treated as described above using 1 ml HFIP and 1 ml DMSO.
Peptide concentrations were adjusted to 60 mM for Ab42 and
100 mM for Ab40 with 50 mM Tris-HCl, 1 mM EDTA (pH
7.4) buffer and the samples contained 10% (vol/vol) 2H2O
(Aldrich, cat. 269786). A 15N–1H heteronuclear single
quantum coherence (HSQC) spectrum for Ab42 was
recorded on a Bruker Avance spectrometer equipped with a
cryoprobe and operating at 700 MHz at 58C. The Ab40
15N–1H-HSQC spectrum was recorded at 258C on a Varian
Inova spectrometer operating at 600 MHz. Spectral assign-
ment was verified using 15N-NOESY-HSQC and
1H,1H-TOCSY experiments. Spectra were processed using
NMRPipe/NMRDraw (Delaglio et al., 1995) and analyzed by
XEASY/CARA software (Bartels et al., 1995).
Cell viability in neuroblastoma cells
Neuroblastoma SH-SY5Y cells (HPA 94030304) were used
with a maximum passage number of 15. Cells were cultured
in Dulbecco’s modified eagle medium (DMEM) 1 ([þ]
4.5 g/l glucose, [þ] L-glutamine, [2] pyruvate) (Gibco, cat.
41965) and 1% (vol/vol) penicillin/streptomycin (Invitrogen,
cat. 15140-122) and 10% (vol/vol) fetal calf serum (Perbio,
cat. SH30070.03) at 378C, 5% CO2 to a confluency of 85%
in a 75 cm2 flask (Greiner Bio-one, cat. 658170). On trypsi-
nization, cells were resuspended at a concentration of
200 000 cells/ml in DMEM/F12 (1:1) [þ]L-glutamine, [þ]
15 mM HEPES (Gibco, cat. 11039), containing 1% (vol/vol)
penicillin/streptomycin (Invitrogen, cat. 15140-122). The
resuspended cells were plated at a volume of 100 ml and a
cell density of 20 000 cells/well in a 96-well plate (BD
Falcon, cat. 353072). The plated cells were incubated for
48 h at 378C at 5% CO2. Ab40 and Ab42 oligomer-enriched
fractions were prepared at a concentration of 100 mM as
described under section ‘Oligomerization and fibrillization of
Ab’ and incubation for 1.5 h under quiescent conditions at
258C. After incubation, the Ab was diluted to final concen-
trations of 1–50 mM in buffer and then diluted 1:1 with pre-
warmed (378C) DMEM/F12 (1:1) [þ]L-glutamine, [þ]
15 mM HEPES (Gibco, cat. 11039), containing 1% (vol/vol)
penicillin/streptomycin (Invitrogen, cat. 15140-122). The Ab
or medium as a control was added at a volume of 100 ml in
medium to each well and left to incubate for 48 h. After
48 h, 10 ml Cell Titer-Bluew Cell Viability Assay (Promega,
cat. G8080) compound was added to each well and incubated
for 4–6 h at 378C to allow viable cells to convert resazurin
into resorufin. Fluorescence intensity of resorufin was
measured on a 96-well plate reader (BMG Labtech, Fluostar
Optima) at an excitation wavelength of 544 nm and an emis-
sion wavelength of 590 nm. Measurements were performed in
three independent experiments and statistical analysis was per-
formed to calculate average values and standard deviations.
Results and discussion
Overview of the protocol and comparison
with other methods
The proposed protocol provides for a method to dissolve
amyloid beta (Ab) peptide via a rapid three-step procedure.
Dissolving recombinant produced Ab42 directly into buffer
shows that a Tht curve to follow the kinetic aspects of the
aggregation curve lacks the typical sigmoidal shape com-
monly observed for aggregating peptides and proteins
(Fig. 1a). No lag phase is apparent and also the Tht fluor-
escence intensity is already increased on starting the assay,
both indicative for the presence of pre-formed seeds or
aggregates in the solution. FT-IR is used for a wide range of
applications and also has shown its applicability in the field
of protein conformation determination (Miyazawa and Blout,
1961). Figure 1b shows that Ab42 that has been prepared
using the proposed three-step dissolving procedure is intrinsi-
cally unstructured directly after solubilization in aqueous
solution, characterized by a broad peak centered around
1654 cm21, but assumes a b-sheet aggregate fold (peak at
1627 cm21) on incubation for 24 h. Figure 1c shows that
directly in buffer dissolved Ab42 already exerts a high
degree of b-sheet structure, while monomeric dissolved
Ab is an intrinsically disordered peptide. These results
underline the necessity to develop an alternative procedure to
dissolve Ab.
We first exploited the structure-promoting properties of
HFIP. From a number of tested alcohols, HFIP was shown to
most effectively denature the model protein b-lactoglobulin
Validated solubilization procedure for Abeta
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and to induce a non-native a-helix conformation (Hirota
et al., 1997). Dilute solutions of HFIP (1–4%) promote fibril
formation of the islet amyloid polypeptide (Padrick and
Miranker, 2002) but concentrated HFIP solutions have been
shown to actively remove pre-formed aggregate seeds from
solutions containing amyloidogenic proteins (Buck, 1998;
Zagorski et al., 1999; Nichols et al., 2005). Later studies con-
firmed similar observations for Ab (Nichols et al., 2005).
HFIP owes its activity due to its high degree of fluorination
and induces helical formation (Hirota-Nakaoka et al., 2003;
Tomaselli et al., 2006). Even though HFIP has been shown
to dissociate fibrils, b2-microglobulin aggregates can resist
the application of this solvent (Hirota-Nakaoka et al., 2003).
The insufficient ability of HFIP to completely dissociate
amyloid fibrils has been ascribed to its non-polar character
that weakens hydrophobic interactions but cannot dissolve
rigid fibrils (Hirota-Nakaoka et al., 2003). Therefore, in the
presented procedure HFIP solubilization is followed by
DMSO, as this polar compound has been shown to comple-
tely dissociate amyloid fibrils based on its ability to destruct
a hydrogen bond network (Kosower, 1958). HFIP can be
removed using oxygen-free nitrogen gas or, alternatively,
argon gas as methionine-35 of the Ab peptide is susceptible
to oxidation (Butterfield and Bush, 2004). A molecular
dynamics simulation of the effects of DMSO on the structure
and function of subtilisin confirmed that DMSO acts as a
highly effective hydrogen bond acceptor and, hence, can
strip away water from the protein surface (Zheng and
Ornstein, 1996). Many published methods to solubilize Ab
suggest preparation of concentrated Ab stock solutions in
DMSO followed by a 10- to 100-fold dilution in buffer to
induce aggregation. However, as a result of the effect of
DSMO on the hydrogen network of proteins, the kinetics and
mechanism of the aggregation of Ab are adversely affected
by the presence of small (5%) concentrations of DMSO
(Fig. 2, and Shen and Murphy, 1995) in a non-
physiologically relevant manner. We therefore apply a
column-exchange step to remove all traces of DMSO. Other
published methods often employ the effects of HCl and
NaOH to aid Ab solubility at a pH far removed from its iso-
electric point ( pH 5.3). In order to adjust the pH of the
solution to approach more physiologically relevant pH values
from an acidic pH requires transition through the isoelectric
point at which the peptide is most prone to aggregate. Also
the addition of these pH-affecting compounds introduces an
additional factor that could induce artifacts in the aggrega-
tion mechanism of Ab.
Experimental design
The protocol for Ab solubilization that provided best results
consists of sequential treatment using HFIP and DMSO fol-
lowed by exchange of DMSO into buffer using a desalting
column (Fig. 3a). The use of a high concentration (100%)
of HFIP, a fluorinated alcohol, provides a means of
Fig. 2 Different solubilization procedures affect the aggregation of Ab. The
presence of traces of DMSO affects the aggregation kinetics of Ab42.
Dilution of concentrated Ab stocks in DMSO into buffer followed by
monitoring of the aggregation rate of Ab by Tht fluorescence. The
aggregation of Ab is linearly inhibited with increasing concentrations of
DMSO.
Fig. 1 Solubilization of Ab42 directly into buffer indicates the presence of
pre-formed aggregates. (a) Comparison of aggregation kinetics probed by
Tht fluorescence of Ab dissolved directly into buffer and the novel proposed
three-step procedure. A concentration of 50 mM Ab was either dissolved
directly into buffer or solubilized using the proposed three-step procedure.
(b) FT-IR spectroscopy of Ab42 dissolved into buffer using the three-step
dissolving procedure. Directly on elution off the column the broad FT-IR
spectrum is characteristic for an unstructured peptide while after 24 h
incubation at a concentration of 100 mM at 258C the intensity at 1627 cm21
increases characteristic for b-sheet amyloid aggregation. (c) FT-IR
spectroscopy of Ab42 dissolved directly into buffer. Directly on
solubilization the spectrum is characteristic for a mixture of unfolded
peptide and b-sheet aggregation with a main intensity at 1627 cm21 and a
broad shoulder at 1654 cm21. After 24 h incubation at a concentration of
100 mM at 258C the intensity at 1627 cm21 increased slightly and the
shoulder at 1654 cm21 is smaller.
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interaction with the backbone and removal of water from the
surface. Subsequently, the HFIP is evaporated off by the use
of oxygen-free nitrogen gas or argon gas that protects the
peptide from oxidative modification. The hydrophobic
methyl groups of DMSO have the ability to then interact
with hydrophobic side chains of the Ab peptide while the
polar S¼O group interacts with water molecules. DMSO is
then removed by buffer exchange using a desalting column
resulting in Ab virtually free from aggregating seeds in
buffer (Fig. 3b). The electrophoretic analysis of the elution
of Ab from the column shows that fractions 2–5 are
enriched with Ab (150–750 ml). Ab40 elutes as a pure
monomeric solution while Ab42 elutes as a primarily
monomeric solution containing small quantities of an
SDS-resistant species with an apparent molecular weight
resembling trimeric Ab. No higher-molecular-weight aggre-
gates were observed. As the presence of small amounts of
HFIP and DMSO can modify the aggregation rates of Ab
(Nichols et al., 2005, and Fig. 2), it is important to validate
their complete removal. We use FT-IR that provides charac-
teristic and sensitive fingerprints for the presence of trace
amounts of HFIP (Czarnik-Matusewicz et al., 2008) or
DMSO. FT-IR spectra of the various elution fractions after
column elution show that with increasing elution fraction the
concentration of DMSO increases (Fig. 3c). It is also shown
that HFIP has been effectively removed during the pro-
cedures supported by the lack of characteristic intensity in
the FT-IR spectrum between 1300 and 1100 cm21. A 1%
DMSO solution in buffer has two characteristic peaks: at
1011 cm21 and one at 951 cm21. Plotting the intensity at
these two wavelengths against the fraction number shows
that only from fraction 9 (1350 ml) up the concentration of
DMSO starts to increase (Fig. 3c). In addition, the absence
of a detectable signal at 2.5 p.p.m., which is characteristic of
DMSO, in the one-dimensional 1H NMR spectrum of the Ab
preparations, confirms that elution of the first 1 ml of Ab
from the column yields DMSO-free Ab (Fig. 3d). The elec-
trospray ionization mass spectrum shows that Ab42, using
the protocol, eluted free of contaminants and without appar-
ent modifications (Fig. 3e), such as dityrosine-formation that
is commonly observed for Ab peptides as a function of oxi-
dation (Yoburn et al., 2003).
We tested the reproducibility of the behavior of the pre-
pared Ab solutions and their performance in a variety of
assays related to aggregate formation or cell viability com-
monly used to study the effects of Ab. Commonly used
Fig. 3 Novel solubilization procedure for Ab leads to primarily monomeric Ab and absence of contaminating chemicals. (a) Treatment of the Ab peptide to
dissolve it into buffer involves sequential dilution in HFIP, and DMSO followed by buffer exchange by means of a desalting column. Details of the procedure
are described in the text. (b) Non-reducing SDS-PAGE analysis of fractions of 150 ml each eluted off the desalting column shows that fractions 2–5 (300–
750 ml) are enriched in Ab peptide. Ab40 is primarily monomeric on elution while Ab42 is primarily monomeric with a small fraction of apparently trimeric
peptide. (c) Up to and including fraction 8 (1200 ml) can be eluted off the desalting column without contamination by DMSO. The intensities of FT-IR peaks
characteristic for the presence of DMSO (1011 and 951 cm21) are plotted against eluted fraction number. (d) One-dimensional 1H NMR spectrum of an Ab42
preparation confirms the complete removal of DMSO because of the absence of characteristic solvent signal at 2.5 p.p.m., as indicated by the arrow. The inset
shows a zoomed-in view of the region from 2 to 3 p.p.m. proton frequency. (e) Electrospray mass spectrum of Ab42 in positive mode with the deconvoluted
spectrum as inset.
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assays to study the aggregation of Ab in vitro consist of thio-
flavin T fluorescence (Hayashi et al., 2004), electron
microscopy (Hayashi et al., 2004; Martins et al., 2008;
Nerelius et al., 2009) and FT-IR (Martins et al., 2008; Cerf
et al., 2009) and the effect of Ab on the toxicity is usually
assayed by viability assays on neuroblastoma cells (Chromy
et al., 2003; Nerelius et al., 2009) or neuronal cultures
(Lambert et al., 1998; Hayashi et al., 2004; Martins et al.,
2008).
Nuclear magnetic resonance
NMR analysis shows that Ab40 and Ab42 prepared by our
procedure are mainly monomeric species as shown by the
sharp resonances in 2D HSQC experiments (Fig. 4). NMR
analysis also assures us that the protocol does not induce oxi-
dation of Met35: oxidation of this residue is known to result
in a notable chemical shift that affects several crosspeaks in
the HSQC (Hou et al., 2004). Our spectra of Ab40 and
Ab42 are in excellent agreement with literature data report-
ing NH of Met35 in the reduced state at 8.5 p.p.m. for the
1H-frequency, while the NH of Met35 of the oxidized state
appeared upfield at 8.8 p.p.m. (Fig. 4a and b, and
Hou et al., 2004). This observation is an important point to
note because pre-treatment with HFIP might occasionally
promote oxidation of the Ab peptide (Hou et al., 2004).
Thioflavin T fluorescence
Tht fluorescence is a useful probe to assay the aggregation of
proteins. The quantum yield for fluorescence of this weakly
fluorescent dye increases strongly on complexation with
amyloid fibrils (Naiki et al., 1989). Fig. 5a shows that differ-
ences in aggregation rates between the aggregating Ab42
and less aggregation-prone Ab40 can be distinguished using
in situ. Tht fluorescence. Reproducibility of the obtained
results is an important parameter to evaluate the quality of
the developed procedures. Figure 5a shows Tht fluorescence
curves obtained for three independent experiments. The stan-
dard error between the experiments is 7–10% and the
differences between the aggregation rates of Ab40 and Ab42
are therefore significant.
Transmission electron microscopy
We used TEM to characterize fibril morphology of aggre-
gates formed by Ab40 and Ab42 on incubation at a concen-
tration of 100 mM for 24 h at 258C. Amyloidogenic Ab42
(Fig. 5b) forms aggregates characterized by short fibrils
which intertwine and appear rigid. Ab40 (Fig. 5c) on the
other hand forms long semi-flexible negatively stained fibrils
with a characteristic periodic twist that is regularly found in
fibrils of other origin, such as insulin (Jime´nez et al., 2002).
Toxicity on SH-SY5Y cells
The toxicity of 1.5 h incubated 100 mM Ab40 and Ab42
preparations was tested using neuroblastoma SH-SY5Y cells
plated at a cell density of 20 000 cells/well in serum-deprived
medium. To this end, Ab preparations were diluted to various
concentrations ranging from 1 to 50 mM in serum-deprived
medium and 100 ml was added to each well in 6-fold. After
48 h incubation cells were tested for cell death using Cell
Titer-Blue viability assay (Promega). Figure 5d shows that
cell viability is Ab concentration dependent and that Ab42
aggregates induce cell death at lower concentrations (from
7.5 mM) compared with Ab40 aggregates (from 30 mM). The
results in Fig. 5d are obtained from three independent
Fig. 4 NMR 15N-1H HSQC spectra of (a) Ab40 and (b) Ab42 recorded at 600 MHz and 25 and 58C, resp. Oxidation of Met35 residue in Ab is prevented by
the novel solubilization procedure. Spectrum assignment is shown only for those crosspeaks that would undergo a chemical shift displacement as a function of
the redox state of Met35 (i.e. Leu34-Met35-Val36 in Ab40 and Leu34-Met35-Val36-Gly37-Gly38 in Ab42) (Hou et al., 2004).
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experiments and the standard error is maximum 12% (for
30 mM Ab40) but in most cases .5%.
Conclusions
A robust and validated three-step procedure is presented to
prepare biocompatible virtually aggregate-free solutions with
an efficient recovery of amyloidogenic Ab42 implicated in
Alzheimer’s disease. The procedure involves the sequential
use of HFIP, DMSO and a column exchange step. While the
use of organic solvents also allows the reliable preparation of
biologically relevant quantities of Ab42 and Ab40 and their
mixtures, the incorporation of a desalting column in the solu-
bilization procedure makes it possible to obtain the Ab
peptide in any desirably buffer system. The resulting Ab
preparation shows highly reproducible biophysical and cell
biological behavior. The use of this protocol may be
extended to the solubilization of other highly amphipathic or
hydrophobic polypeptides.
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